CareDx, Inc. · NASDAQ:CDNA

CareDx — Q3 2019 Earnings Presentation

28 slides from CareDx's earnings presentation, November 2019

  1. Slide 1: Corporate Presentation

    Corporate Presentation Margot Duane November 2019 Stem Cell Transplant Recipient 27, 2019

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding future financial position of CareDx, Inc. (together with its subsidiari

  3. Slide 3: Our Vision and Mission

    OUR VISION The Leading Partner for Transplant Patients and The Transplant Ecosystem OUR MISSION We are committed to improving Transplant Patient Outcomes by providing Innovative and Intelligent Solutions throughout the entire Patient Journey 3

  4. Slide 4: CareDx Highlights

    CareDx Highlights Leader in Transplantation − Provider of leading solutions across continuum of transplantation − Technology leadership position in Molecular Diagnostics with (“Liquid Biopsy”) and Gene Expression profiling − Leader in continuum of care along the transplant patient journey Transforma

  5. Slide 5: YTD 2019 Highlights

    YTD 2019 Highlights • AlloSure Launch Progress 7% US Kidney Tx Patients ✓ • KOAR >1,000 patients, SHORE & OKRA initiated ✓ • KidneyCare and HeartCare advanced ✓ • OTTR & Xyn acquisition, iBox addition ✓ • AlloSeq cfDNA and AlloSeq Tx 17 launched ✓ 5

  6. Slide 6: Experienced Management Team

    Experienced Management Team Peter Maag McKinsey, Novartis Pharma, Ardelyx, AstraZeneca / Reg Seeto Chief Executive Officer Novartis Diagnostics Medimmune, Organon President, CBO BioSciences, Boehringer Novartis Vaccines & Diagnostics, Paul Ciccolella Michael Bell Pacific Biosciences, Affymetrix, Sen

  7. Slide 7: Better Matching + Better Surveillance = Better Outcomes

    Better Matching + Better Surveillance = Better Outcomes 7

  8. Slide 8: CareDx – 20 Years of Focus on Transplantation

    CareDx – 20 Years of Focus on Transplantation Transplant Evolution during last 5 years to deliver on vision Leader … Global Operations Launched Heartcare (via SHORE) Pipeline / Launched QTYPE (PCR HLA) Platform Licensed NGS Tx- Portfolio (Illumina) Leader Launched AlloSure first dd-cfDNA Renal Tx Ac

  9. Slide 9: CareDx's Solutions Target Long-Term Outcomes

    CareDx’s Solutions Target Long-Term Outcomes Conceptual Years 13 10 Compliance Standardization Immuno and and Modulation Adherence Personalization Current Future Survival Survival

  10. Slide 10: Building a Moat in Transplantation

    Building a Moat in Transplantation Evolution during next 12 months for longitudinal and long-term patient management Leader in Long-Term Patient Outcomes Global Launch new global offerings Global Leader in Operations New pipeline programs - Tx specific the Field of Transplantation Pipeline / New pla

  11. Slide 11: Business Lines Focused On +$4bn TAM Opportunity

    Business Lines Focused On +$4bn TAM Opportunity Testing Services Products Digital Opportunity Opportunity Opportunity Market US Transplant Global Transplant Global Transplant IT 300,000 Patients > 3 M Patients, Annual Volume 1.5 M Patients 700,000 Waitlists Donors, Caregivers 250 Centers 1,000 Globa

  12. Slide 12: CareDx In Market Products

    CareDx In Market Products Business Approach Solution Testing Services • Capitalize on first mover with AlloSure 84%* • Build on existing legacy of AlloMap Products • Provide fastest turnaround typing with QType 12% • Deep sequencing information with NGS • Build on existing relationship in Solid Orga

  13. Slide 13: CareDx Transplant Solutions Pipeline

    CareDx Transplant Solutions Pipeline Business Approach Solution Testing Services • Increase menu by multi-modality testing • Provide AlloSure for other organs • Anchor with best in class typing products Products • Grow globally with cfDNA technology • Expand transplant EMR with Cerner & EPIC Digital

  14. Slide 14: Strategic Advantage From Large Multi-Center Clinical Studies

    Strategic Advantage From Large Multi-Center Clinical Studies Start Study Impact Centers Patients Samples 2019 OKRA Long-Term Kidney Outcomes >50 > 4000 > 10,000 2018 SHORE Long-term Heart Transplant Outcomes >40 > 1000 > 8,000 2018 K-OAR Long-term Kidney Transplant Outcomes >50 > 1000 > 8,000 2015 D

  15. Slide 15: AlloSure Metrics - Continued Momentum

    AlloSure Metrics - Continued Momentum Launch Metrics Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Patient Results (in qtr) 3,708 4,575 5,710 7,355 8,524 Unique Patients Tested (in qtr) 2,829 3,377 4,284 5,548 6,597 Ordering Centers (in qtr) 86 100 101 117 124 KOAR Enrolled Centers (cum) 40 47 50 51 53 KO

  16. Slide 16: CareDx's Approach to Precision Medicine in Transplantation

    CareDx’s Approach to Precision Medicine in Transplantation Artificial Intelligence Transplant Transplant Care Care Genomic HeartCare AiTraC - Comprehensive Biomarkers KidneyCare - Actionable - Multimodality Care Pathways AlloMap - Protocolized - Integrated into AlloSure Surveillance EMR - High Value

  17. Slide 17: The Latest Innovation in Transplant Surveillance

    The Latest Innovation in Transplant Surveillance Donor-derived Cell-free Gene Expression Machine learning DNA (dd-cfDNA) Profiling (GEP) transplant data analytics Graft Injury Immune Activity Graft Prognosis 17

  18. Slide 18: Digital Transformation in Transplant Care

    Digital Transformation in Transplant Care Evaluation Surgery Post Op Lab Visit Office Visit Chronic Condition Wait List End State Disease Life-Long Immunosuppression Organ Matching Adherence Surveillance ✓ ▪ Donor identification ▪ Interventions ▪ Observations ▪ Timely organ ▪ Rx personalization ▪ Bi

  19. Slide 19: Growing Global Presence Across Transplantation Labs

    Growing Global Presence Across Transplantation Labs Strategy ▪ Patient Dedication Transplant CareDx Region ▪ Clinical & Premium Positioning HLA Labs Penetration ▪ Pre-Post Transplant Continuum ▪ Multi-Product Offerings Europe 300 80% Assets North America 200 79% ▪ Strong Reputation & Brands ▪ Broad

  20. Slide 20: Building a Moat in Transplant Care

    Building a Moat in Transplant Care Total US Transplant Centers Strategy ▪ Transplant Center Focused AlloSure/ ▪ Multiple Touch Points (Village Concept) AlloMap Customers ▪ Pan-Organ Offerings K-OAR Digital Customers Centers Approach ▪ Based on Clinical Evidence ▪ Tailored to Center Workflow ▪ Improv

  21. Slide 21: 60% Revenue Growth in Q3 2019

    60% Revenue Growth in Q3 2019 Q3 Patient Results Test 2018A 2019A YoY% Heart 4,080 4,726 16% Kidney 3,708 8,524 130% Q3 Revenue ($ millions) 2018A 2019A +60% +68% 33.8 28.2 21.2 16.8 -1% 4.2 4.2 1.4 Testing Services Products Digital & Other Total 21

  22. Slide 22: Fifth Consecutive Profitable Quarter in Q3 2019

    Fifth Consecutive Profitable Quarter in Q3 2019 ($ millions) Non-GAAP* Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Total Revenue 21.2 23.5 26.0 31.5 33.8 Gross Margin % 61% 59% 67% 67% 69% Operating Expense 13.0 13.5 16.1 21.3 23.2 Adjusted EBITDA 0.2 0.8 1.8 0.1 0.8 Operating Cash Flow 0.4 2.0 (5.9) 3.

  23. Slide 23: Strong, Debt-Free Balance Sheet

    Strong, Debt-Free Balance Sheet Cash & Debt at 9/30/19 Common Stock at 9/30/19 $ millions # millions Cash & Cash Equivalents 40.9 Outstanding Common Stock 42.4 Debt - Stock Options / RSUs 4.2 Warrants 0.4 Fully Diluted Common Stock 47.0 23

  24. Slide 24: FY 2019 Revenue Guidance

    FY 2019 Revenue Guidance Revenue Growth Drivers $124m- $125m • OTTR Acquisition Digital $4m - $5m • Xyn Acquisition • 50 Center Penetration $77m AlloSure >100% • KOAR Registry Kidney • OKRA Registry AlloMap • HeartCare Protocol >10% Heart • SHORE Registry Products ~20% • NGS Launches • QTYPE adoptio

  25. Slide 25: Our Vision and Mission

    OUR VISION The Leading Partner for Transplant Patients and The Transplant Ecosystem OUR MISSION We are committed to improving Transplant Patient Outcomes by providing Innovative and Intelligent Solutions throughout the entire Patient Journey 25

  26. Slide 26: Appendix

    Appendix é CareDx°

  27. Slide 27: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted $ million Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP net income, non-GAAP net loss, non-GAAP basic and diluted net incom

  28. Slide 28: Reconciliation of Non-GAAP Financial Measures

    Reconciliation of Non-GAAP Financial Measures $ million Q3 Q4 Q1 Q2 Q3 2018 2018 2019 2019 2019 GAAP Net Loss (20.0) (3.8) (7.5) (7.8) (1.8) Stock-based compensation expense 1.9 2.1 6.1 5.0 6.0 Acquisition-related amortization of purchased intangibles 0.8 0.7 0.7 0.8 0.9 Acquisition related fees and

CareDx — Q3 2019 Earnings Presentation on 6ix